|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.78 USD | -0.45% |
|
+5.53% | +2.72% |
| 15/05 | Qiagen's Updated Clinical Decision Support Platform Secures EU Certification | MT |
| 14/05 | QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret | CI |
Qiagen N.V. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 458.8 million compared to USD 485.4 million a year ago. Net income was USD 80.67 million compared to USD 85.04 million a year ago.
Diluted earnings per share from continuing operations was USD 0.36 compared to USD 0.3814 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.72% | 1.02TCr | |
| +33.37% | 5.08TCr | |
| +1.55% | 4.28TCr | |
| +49.28% | 4.2TCr | |
| -4.22% | 2.95TCr | |
| +11.57% | 2.61TCr | |
| -21.00% | 1.91TCr | |
| +7.36% | 1.31TCr | |
| +28.30% | 1.22TCr | |
| +23.80% | 1.21TCr |
QIAGEN N.V. 
